

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:10:25 ON 19 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 AUG 2002 HIGHEST RN 444143-26-4
DICTIONARY FILE UPDATES: 16 AUG 2002 HIGHEST RN 444143-26-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d l83 ide can tot

L83 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 1118-68-9 REGISTRY

CN Glycine, N,N-dimethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN (Dimethylamino)acetic acid

CN 2-(Dimethylamino)acetic acid

CN Dimethylglycine

CN N,N-Dimethylaminoacetic acid

CN N,N-Dimethylglycine

CN N-Methylsarcosine

FS 3D CONCORD

MF C4 H9 N O2

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*,
IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PROMT, RTECS*, SPECINFO,
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Me₂N-CH₂-CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

616 REFERENCES IN FILE CA (1967 TO DATE)

57 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

618 REFERENCES IN FILE CAPLUS (1967 TO DATE)

29 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:78865

REFERENCE 2: 137:78769

REFERENCE 3: 137:73245

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

REFERENCE 4: 137:63245
REFERENCE 5: 137:17423
REFERENCE 6: 137:699
REFERENCE 7: 136:385950
REFERENCE 8: 136:365608
REFERENCE 9: 136:355074
REFERENCE 10: 136:340597

L83 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 590-46-5 REGISTRY

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Betaine, hydrochloride (8CI)

OTHER NAMES:

CN (Carboxymethyl)trimethylammonium chloride

CN 1-Carboxy-N,N,N-trimethylmethanaminium chloride

CN Achylin

CN Acidin

CN Acidine

CN Acidogeno

CN Acidol

CN Acidol hydrochloride

CN Acinorm

CN Acipepsol

CN Aciventral forte

CN Betaine chloride

CN Glycine betaine hydrochloride

CN Glycocoll betaine hydrochloride

CN Pluchine

CN Rubrine C hydrochloride

DR 11042-13-0, 141-58-2, 125883-10-5, 67332-80-3

MF C5 H12 N O2 . Cl

CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DETHERM*, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (6915-17-9)

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CO}_2\text{H}$

● Cl^-

199 REFERENCES IN FILE CA (1967 TO DATE)

11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

200 REFERENCES IN FILE CAPLUS (1967 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:95266

REFERENCE 2: 137:62989
REFERENCE 3: 136:325827
REFERENCE 4: 136:74665
REFERENCE 5: 136:31680
REFERENCE 6: 136:31656
REFERENCE 7: 135:297518
REFERENCE 8: 135:242394
REFERENCE 9: 135:161601
REFERENCE 10: 135:154646

L83 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 107-97-1 REGISTRY

CN Glycine, N-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Sarcosine (8CI)

OTHER NAMES:

CN (Methylamino)acetic acid

CN (Methylamino)ethanoic acid

CN Acetic acid, (methylamino)-

CN Methylglycine

CN N-Methylaminoacetic acid

CN N-Methylglycine

CN Sarcosin

CN Sarcosinic acid

FS 3D CONCORD

MF C3 H7 N O2

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE,
GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS,
NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER,
TULSA, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

MeNH-CH₂-CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2057 REFERENCES IN FILE CA (1967 TO DATE)

427 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2063 REFERENCES IN FILE CAPLUS (1967 TO DATE)

41 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114249
REFERENCE 2: 137:114239
REFERENCE 3: 137:109409

REFERENCE 4: 137:92949
REFERENCE 5: 137:63240
REFERENCE 6: 137:63136
REFERENCE 7: 137:52055
REFERENCE 8: 137:49890
REFERENCE 9: 137:47146
REFERENCE 10: 137:38714

L83 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 107-43-7 REGISTRY

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ammonium compounds, substituted, (carboxymethyl)trimethyl-, hydroxide, inner salt (7CI)

CN **Betaine (8CI)**

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, hydroxide, inner salt

OTHER NAMES:

CN (Carboxymethyl)trimethylammonium hydroxide inner salt

CN (Trimethylammonio)acetate

CN .alpha.-Earleine

CN Abromine

CN Aminocoat

CN Aquadew AN 100

CN Betafin

CN Betafin BCR

CN Betafin BP

CN Cystadane

CN FinnStim

CN Glycine betaine

CN Glycine, trimethylbetaine

CN Glycocol betaine

CN Glycylbetaine

CN Greenstim

CN Loramine AMB 13

CN Lycine

CN N,N,N-Trimethylglycine

CN Oxyneurine

CN Rubrine C

CN Trimethylglycine

CN Trimethylglycocol

FS 3D CONCORD

DR 11042-12-9, 590-30-7, 24980-93-6, 45631-77-4

MF C5 H11 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Me₃⁺N-CH₂-CO₂⁻

3412 REFERENCES IN FILE CA (1967 TO DATE)
537 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3419 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114511
REFERENCE 2: 137:114201
REFERENCE 3: 137:108448
REFERENCE 4: 137:106179
REFERENCE 5: 137:105978
REFERENCE 6: 137:99518
REFERENCE 7: 137:99009
REFERENCE 8: 137:95266
REFERENCE 9: 137:91680
REFERENCE 10: 137:90665

L83 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 56-45-1 REGISTRY

CN L-Serine (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Serine, L- (8CI)

OTHER NAMES:

CN (-)-Serine

CN (S)-.alpha.-Amino-.beta.-hydroxypropionic acid

CN (S)-2-Amino-3-hydroxypropanoic acid

CN (S)-Serine

CN .beta.-Hydroxy-L-alanine

CN L-(-)-Serine

CN L-3-Hydroxy-2-aminopropionic acid

CN L-Alanine, 3-hydroxy-

CN L-Ser

CN Propanoic acid, 2-amino-3-hydroxy-, (S)-

CN Serine

FS STEREOSEARCH

DR 6898-95-9

MF C3 H7 N O3

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


25066 REFERENCES IN FILE CA (1967 TO DATE)
 693 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 25098 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114496
 REFERENCE 2: 137:114239
 REFERENCE 3: 137:114200
 REFERENCE 4: 137:109469
 REFERENCE 5: 137:108613
 REFERENCE 6: 137:108602
 REFERENCE 7: 137:108531
 REFERENCE 8: 137:108497
 REFERENCE 9: 137:108465
 REFERENCE 10: 137:108462

=> d l85 ide can tot

L85 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2002 ACS
 RN **139418-88-5** REGISTRY
 CN L-Glutamic acid, N-[4-[(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N7 O6 . x Ca
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 CRN (134-35-0)

Absolute stereochemistry.



●x Ca

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:11204
REFERENCE 2: 135:357075
REFERENCE 3: 132:326081
REFERENCE 4: 132:326078
REFERENCE 5: 116:129615

L85 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2002 ACS

RN 10360-12-0 REGISTRY

CN Imidazo[1,5-f]pteridinium, 3-amino-8-[4-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]phenyl]-1,2,5,6,6a,7-hexahydro-1-oxo-, (6aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Imidazo[1,5-f]pteridinium, 3-amino-8-[4-[[[(1,3-dicarboxypropyl)amino]carbonyl]phenyl]-1,2,5,6,6a,7-hexahydro-1-oxo-

CN Imidazo[1,5-f]pteridinium, 3-amino-8-[p-[(1,3-dicarboxypropyl)carbamoyl]phenyl]-5,6,6a,7-tetrahydro-1-hydroxy- (8CI)

OTHER NAMES:

CN 5,10-Methenyltetrahydrofolic acid

CN Folic acid, tetrahydro-N9,N10-methylidyne-

CN N5,N10-Methenyltetrahydrofolic acid

FS STEREOSEARCH


DR 16531-85-4, 102274-60-2, 65981-92-2, 73611-11-7, 88830-88-0, 40245-00-9, 49553-77-7

MF C20 H22 N7 O6

CI COM

LC STN Files: AGRICOLA, CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



80 REFERENCES IN FILE CA (1967 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 80 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:114515
 REFERENCE 2: 136:345818
 REFERENCE 3: 136:107523
 REFERENCE 4: 136:11204
 REFERENCE 5: 136:4848
 REFERENCE 6: 135:357075
 REFERENCE 7: 135:356337
 REFERENCE 8: 135:148597
 REFERENCE 9: 134:127680
 REFERENCE 10: 133:219369

L85 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2002 ACS

RN 3432-99-3 REGISTRY

CN L-Glutamic acid, N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, N-[p-(3-amino-5,6,6a,7-tetrahydro-1-hydroxyimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-, L- (8CI)

CN Imidazo[1,5-f]pteridine, L-glutamic acid deriv.

OTHER NAMES:

CN (+)-5,10-Methylene-5,6,7,8-tetrahydrofolic acid

CN 5,10-Methylene-5,6,7,8-tetrahydrofolic acid

CN 5,10-Methylenetetrahydrofolic acid

CN Folic acid, tetrahydro-N5,N10-methylene-

CN N5,N10-Methylene-5,6,7,8-tetrahydrofolic acid

CN N5,N10-Methylenetetrahydrofolic acid

CN **N5,N10-Methylenetetrahydropteroylglutamic acid**

FS STEREOSEARCH

DR 14948-92-6, 23284-08-4, 39939-22-5, 42578-82-5


MF C20 H23 N7 O6

CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE, MEDLINE, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

438 REFERENCES IN FILE CA (1967 TO DATE)
 51 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 438 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114515
 REFERENCE 2: 137:29715
 REFERENCE 3: 136:345818
 REFERENCE 4: 136:163249
 REFERENCE 5: 136:107523
 REFERENCE 6: 136:11204
 REFERENCE 7: 136:4848
 REFERENCE 8: 135:357075
 REFERENCE 9: 135:355679
 REFERENCE 10: 135:315433

L85 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2002 ACS

RN 2800-34-2 REGISTRY

CN L-Glutamic acid, N-[4-[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny)methyl]formylamino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, N-[p-[N-[(2-amino-5,6,7,8-tetrahydro-4-hydroxy-6-pteridiny)methyl]formamido]benzoyl]- (7CI)

CN Glutamic acid, N-[p-[N-[(2-amino-5,6,7,8-tetrahydro-4-hydroxy-6-pteridiny)methyl]formamido]benzoyl]-, L- (8CI)

OTHER NAMES:

CN 10-Formyl-5,6,7,8-tetrahydrofolic acid

CN 10-Formyltetrahydrofolate

CN 10-Formyltetrahydrofolic acid

CN 10-Formyltetrahydropteroylglutamic acid

CN N10-Formyl-5,6,7,8-tetrahydrofolic acid

CN N10-Formyltetrahydrofolate


CN N10-Formyltetrahydrofolic acid

CN N10-Formyltetrahydropteroylglutamate

FS STEREOSEARCH

DR 18656-95-6
MF C20 H23 N7 O7
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CANCERLIT, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, MEDLINE, NIOSHTIC,
TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

278 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
278 REFERENCES IN FILE CAPLUS (1967 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114515
REFERENCE 2: 136:397744
REFERENCE 3: 136:345818
REFERENCE 4: 136:306536
REFERENCE 5: 136:107523
REFERENCE 6: 136:83063
REFERENCE 7: 136:11204
REFERENCE 8: 136:4848
REFERENCE 9: 135:357075
REFERENCE 10: 135:355679

L85 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2002 ACS

RN 134-35-0 REGISTRY

CN L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridiny1)methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, N-[p-[[(2-amino-5,6,7,8-tetrahydro-4-hydroxy-5-methyl-6-pteridiny1)methyl]amino]benzoyl]-, L- (8CI)


CN Glutamic acid, N-[p-[[(2-amino-5,6,7,8-tetrahydro-4-hydroxy-5-methyl-6-pteridiny1)methyl]amino]benzoyl]- (6CI)

OTHER NAMES:

CN 5-Methyl-5,6,7,8-tetrahydrofolic acid

CN 5-Methyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
CN 5-Methyltetrahydrofolic acid
CN 5-Methyltetrahydropteroyl monoglutamate
CN 5-Methyltetrahydropteroylglutamic acid
CN N-Methyltetrahydrofolate
CN N-Methyltetrahydrofolic acid
CN N5-Methyltetrahydrofolate
CN N5-Methyltetrahydrofolic acid
CN N5-Methyltetrahydropteroylglutamate
CN Prefolic A
FS STEREOSEARCH
DR 3922-58-5, 76937-22-9
MF C20 H25 N7 O6
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CIN, DDFU, DRUGU,
EMBASE, IPA, MEDLINE, NIOSHTIC, PROMT, TOXCENTER, USPATFULL, VETU
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1016 REFERENCES IN FILE CA (1967 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1018 REFERENCES IN FILE CAPLUS (1967 TO DATE)
16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114515
REFERENCE 2: 137:74540
REFERENCE 3: 137:57568
REFERENCE 4: 137:41508
REFERENCE 5: 136:345818
REFERENCE 6: 136:278642
REFERENCE 7: 136:262429
REFERENCE 8: 136:216022
REFERENCE 9: 136:216020
REFERENCE 10: 136:164421

L85 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2002 ACS
RN 58-05-9 REGISTRY

CN L-Glutamic acid, N-[4-[[[2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, N-[p-[[[2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridiny]methyl]amino]benzoyl]-, L- (8CI)

OTHER NAMES:

CN 10-Formyl-7,8-dihydrofolic acid
 CN 5-Formyl-5,6,7,8-tetrahydrofolic acid
 CN 5-Formyltetrahydrofolic acid
 CN 5-Formyltetrahydropteroylglutamic acid

CN Folinic acid
 CN Folinic acid-SF

CN 1-Leucovorin

CN Leucal

CN Leucovorin

CN Leucovorin

CN Levoleucovorin

CN N5-Formyl-5,6,7,8-tetrahydrofolic acid

CN N5-Formyltetrahydrofolic acid

CN Welcovarin

FS STEREOSEARCH

DR 641-41-8, 121521-95-7, 17435-36-8, 3102-53-2, 33299-78-4, 34786-59-9, 40244-99-3

MF C20 H23 N7 O7

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHARMASEARCH, PROMT, TOXCENTER, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1741 REFERENCES IN FILE CA (1967 TO DATE)

38 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1743 REFERENCES IN FILE CAPLUS (1967 TO DATE)

10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114515

REFERENCE 2: 137:103549

REFERENCE 3: 137:103542

REFERENCE 4: 137:98838
REFERENCE 5: 137:90156
REFERENCE 6: 137:88442
REFERENCE 7: 137:88084
REFERENCE 8: 137:88040
REFERENCE 9: 137:88039
REFERENCE 10: 137:87943

L85 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2002 ACS

RN 56-86-0 REGISTRY

CN L-Glutamic acid (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, L- (7CI, 8CI)

OTHER NAMES:

CN (2S)-2-Aminopentanedioic acid

CN (S)-(+)-Glutamic acid

CN (S)-2-Aminopentanedioic acid

CN (S)-Glutamic acid

CN .alpha.-Aminoglutaric acid

CN .alpha.-Glutamic acid

CN 1-Aminopropane-1,3-dicarboxylic acid

CN 2-Aminoglutaric acid

CN 2-Aminopentanedioic acid

CN 317: PN: WO0214478 SEQID: 316 claimed sequence

CN Aciglut

CN Glusate

CN Glutacid

CN **Glutamic acid**

CN ~~Glutamicol~~

CN Glutamidex

CN Glutaminic acid

CN Glutaminol

CN Glutaton

CN L-(+)-Glutamic acid

CN L-.alpha.-Aminoglutaric acid

CN L-Glutaminic acid

CN 1-Glutaminic acid

CN Pentanedioic acid, 2-amino-, (S)-

FS STEREOSEARCH

DR 6899-05-4, 10549-13-0, 138-16-9

MF C5 H9 N O4

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

48594 REFERENCES IN FILE CA (1967 TO DATE)
 1618 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 48646 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 137:114612
 REFERENCE 2: 137:114508
 REFERENCE 3: 137:114496
 REFERENCE 4: 137:114250
 REFERENCE 5: 137:114249
 REFERENCE 6: 137:114239
 REFERENCE 7: 137:114206
 REFERENCE 8: 137:114200
 REFERENCE 9: 137:113929
 REFERENCE 10: 137:113568

=> d 184 ide can tot

L84 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 20229-56-5 REGISTRY

CN 4H-1-Benzopyran-4-one, 2-[4-(.beta.-D-glucopyranosyloxy)-3-hydroxyphenyl]-
 3,5,7-trihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Spireoside (6CI, 7CI, 8CI)

OTHER NAMES:

CN Quercetin 4'-.beta.-D-glucopyranoside

CN Quercetin 4'-glucoside

CN Quercetin 4'-O-.beta.-D-glucopyranoside

CN Quercetin 4'-O-.beta.-glucopyranoside

CN Quercetin 4'-O-glucoside

CN Spiraein

CN Spiraein (Acacia)

CN **Spiraeosid**

CN Spiraeoside

FS STEREOSEARCH

DR 27459-69-4

MF C21 H20 O12


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM,
 DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, RTECS*, TOXCENTER
 (*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

128 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 129 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:68154
 REFERENCE 2: 137:27775
 REFERENCE 3: 136:385095
 REFERENCE 4: 136:380112
 REFERENCE 5: 136:308933
 REFERENCE 6: 136:276441
 REFERENCE 7: 136:221722
 REFERENCE 8: 136:183123
 REFERENCE 9: 136:144998
 REFERENCE 10: 136:95573

L84 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN **491-50-9** REGISTRY

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-3,5-dihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Quercimeritrin (6CI, 7CI, 8CI)**

OTHER NAMES:

CN C.I. 75710

CN Quercetin 7-.beta.-D-glucopyranoside

CN Quercetin 7-O-.beta.-D-glucopyranoside

CN Quercetin 7-O-.beta.-D-glucoside

CN Quercimeritroside

FS STEREOSEARCH


DR 133-97-1, 1331-97-1, 30113-30-5

MF C21 H20 O12

CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, RTECS*, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

282 REFERENCES IN FILE CA (1967 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 282 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:68154
 REFERENCE 2: 137:44207
 REFERENCE 3: 137:27775
 REFERENCE 4: 136:276441
 REFERENCE 5: 136:244428
 REFERENCE 6: 136:221722
 REFERENCE 7: 136:11204
 REFERENCE 8: 136:2955
 REFERENCE 9: 135:315866
 REFERENCE 10: 135:195716

L84 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 482-36-0 REGISTRY

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Hyperin (7CI, 8CI)

OTHER NAMES:

CN 3,3',4',5,7-Pentahydroxyflavone 3-O-.beta.-D-galactopyranoside

CN 3-O-.beta.-D-Galactopyranosyl quercetin

CN 3-O-.beta.-D-galactopyranosylquercetin

CN Hyperosid

CN Hyperoside


CN Quercetin 3-.beta.-D-galactoside

CN Quercetin 3-.beta.-galactoside

CN Quercetin 3-galactoside

CN Quercetin 3-O-.beta.-D-galactopyranoside
 CN Quercetin 3-O-.beta.-D-galactoside
 CN Quercetin 3-O-.beta.-galactoside
 FS STEREOSEARCH
 DR 158560-10-2, 56552-81-9, 63003-36-1, 61277-37-0, 112457-37-1, 71184-39-9,
 26857-03-4, 28986-85-8, 29224-70-2, 31710-72-2
 MF C21 H20 O12
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, CHEMINFORMRX,
 CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, PROMT,
 RTECS*, SPECINFO, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1309 REFERENCES IN FILE CA (1967 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1314 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE	1:	137:88410
REFERENCE	2:	137:83745
REFERENCE	3:	137:83480
REFERENCE	4:	137:75393
REFERENCE	5:	137:68154
REFERENCE	6:	137:68136
REFERENCE	7:	137:60374
REFERENCE	8:	137:60293

REFERENCE 9: 137:60273

REFERENCE 10: 137:60260

L84 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 482-35-9 REGISTRY

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Hirsutrin (8CI)

OTHER NAMES:

CN 3',4',5,7-Tetrahydroxyflavone-3-.beta.-D-glucopyranoside

CN 3-Glucosylquercetin

CN 3-O-.beta.-D-Glucopyranosylquercetin

CN Contigoside B

CN Glucosyl-3-quercetin

CN Isoquercetin

CN Q 5

CN Quercetin 3-.beta.-D-glucopyranoside

CN Quercetin 3-.beta.-D-glucoside

CN Quercetin 3-.beta.-glucoside

CN Quercetin 3-D-glucoside

CN Quercetin 3-glucoside

CN Quercetin 3-mono-D-glucoside

CN Quercetin 3-monoglucoside

CN Quercetin 3-O-.beta.-D-glucopyranoside

CN Quercetin 3-O-.beta.-D-glucoside

CN Quercetin 3-O-.beta.-glucoside

CN Quercetin 3-O-glucopyranoside

CN Quercetin 3-O-glucoside

CN Quercetin 3.beta.-glucoside

CN Quercetin 3.beta.-O-glucoside

CN Quercetin glucoside

CN Quercetol 3-glucoside

CN Quercetol 3-monoglucoside

FS STEREOSEARCH


DR 133946-90-4, 61277-38-1, 27215-07-2, 28454-82-2, 107438-55-1, 355806-24-5

MF C21 H20 O12

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMINFORMRX, DDFU, DRUGU,
EMBASE, IPA, NAPRALERT, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1222 REFERENCES IN FILE CA (1967 TO DATE)
 19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1225 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 18 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:106502
 REFERENCE 2: 137:83483
 REFERENCE 3: 137:78170
 REFERENCE 4: 137:75393
 REFERENCE 5: 137:60710
 REFERENCE 6: 137:60374
 REFERENCE 7: 137:57502
 REFERENCE 8: 137:44253
 REFERENCE 9: 137:44232
 REFERENCE 10: 137:44228

L84 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 153-18-4 REGISTRY

CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Flavone, 3,3',4',5,5',7-hexahydroxy-, (6-O-.alpha.-L-rhamnosyl-.beta.-D-glucoside) (7CI)

CN Ilixanthin (6CI)

CN **Rutin (8CI)**


OTHER NAMES:

CN 3,3',4',5,7-Pentahydroxyflavone 3-O-rutinoside

CN 3,3',4',5,7-Pentahydroxyflavone 3-rutinoside

CN 3-Rutinosylquercetin
CN 5,7,3',4'-Tetrahydroxyflavonol-3-O-rutinoside
CN Birutan
CN C.I. 75730
CN Eldrin
CN Globulariacitrin
CN Globularicitrin
CN Melin
CN Myrticalorin
CN Myrticolorin
CN Myticolorin
CN Osyritin
CN Osyritrin
CN Oxyritin
CN Paliuroside
CN Phytomelin
CN Quercetin 3-.beta.-rutinoside
CN Quercetin 3-O-.beta.-D-rutinoside
CN Quercetin 3-O-.beta.-rutinoside
CN Quercetin 3-O-rutinoside
CN Quercetin 3-rhamnoglucoside
CN Quercetin 3-rutinoside
CN Rutabion
CN Rutinic acid
CN Rutosid
CN Rutoside
CN Sophorin
CN Tanrutin
CN Violaquercitrin
FS STEREOSEARCH
DR 164535-43-7, 1416-01-9, 158560-09-9, 56764-99-9, 18449-50-8, 146525-66-8,
48197-72-4, 115888-40-9
MF C27 H30 O16
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES,
DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN,
USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4666 REFERENCES IN FILE CA (1967 TO DATE)
 194 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 4682 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:108484
 REFERENCE 2: 137:108470
 REFERENCE 3: 137:106523
 REFERENCE 4: 137:106500
 REFERENCE 5: 137:103062
 REFERENCE 6: 137:99014
 REFERENCE 7: 137:91079
 REFERENCE 8: 137:88410
 REFERENCE 9: 137:83745
 REFERENCE 10: 137:83480

L84 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 117-39-5 REGISTRY

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI)
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Flavone, 3,3',4',5,7-pentahydroxy- (7CI, 8CI)


CN Flavone, 3,4',5,5',7-pentahydroxy- (6CI)

OTHER NAMES:

CN 3,3',4',5,7-Pentahydroxyflavone

CN 3,5,7,3',4'-Pentahydroxyflavone

CN C.I. 75670
CN C.I. Natural Yellow 10
CN Cyanidelonon 1522
CN Meletin
CN **Quercetin**
CN Quercetine
CN Quercetol
CN Quercitin
CN Quertin
CN Quertine
CN Sophoretin
CN Xanthaurine
FS 3D CONCORD
DR 73123-10-1, 74893-81-5
MF C15 H10 O7
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DETERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT,
IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR,
PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USPAT2,
USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7384 REFERENCES IN FILE CA (1967 TO DATE)
567 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7402 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:114641
REFERENCE 2: 137:114336
REFERENCE 3: 137:114233
REFERENCE 4: 137:108659
REFERENCE 5: 137:108484
REFERENCE 6: 137:106502
REFERENCE 7: 137:106500
REFERENCE 8: 137:106075
REFERENCE 9: 137:105822
REFERENCE 10: 137:105653

=> d his

(FILE 'HOME' ENTERED AT 07:15:39 ON 19 AUG 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:15:52 ON 19 AUG 2002

E BETAINE/CN
L1 1 S E3
L2 5 S C5H12NO2/MF AND TRIMETHYL
L3 1 S L2 NOT (D/ELS OR LABELED)
L4 2 S L1,L3
L5 1 S DIMETHYLGLYCINE/CN
L6 1 S SARCOSINE/CN
L7 3 S 56-45-1 OR 312-84-5 OR 302-84-1
L8 7 S L4-L7
SEL RN
L9 679 S E1-E7/CRN
L10 7 S (HYPERIN OR ISOQUERCETIN OR QUERCETIN OR ISOQUERCITRIN OR QUE
SEL RN
L11 283 S E8-E14/CRN

FILE 'HCAPLUS' ENTERED AT 07:23:20 ON 19 AUG 2002

L12 31449 S L8
L13 1619 S L9
L14 102306 S BETAINE OR DIMETHYLGLYCINE OR (DIMETHYL OR DIME OR DI METHYL)
L15 107742 S L12-L14
L16 11178 S L10
L17 625 S L11
L18 14695 S HYPERIN OR ISOQUERCETIN OR QUERCETIN OR ISOQUERCITRIN OR QUER
L19 16007 S L16-L18
L20 637 S BIOFLAVONOID
E BIOFLAVONOID/CT
E E4+ALL
L21 139 S E2
E FLAVONOID/CT
E E6+ALL
L22 22507 S E4,E5,E21-E28,E36,E37,E46,E47,E48,E51,E52,E54
L23 27425 S L19-L22
E AGLYCON/CT
E E4_ALL
E AGLYCON/CT
E E4+ALL
L24 902 S E2
L25 29594 S E22
L26 53908 S L23,L24,L25
L27 640 S L15 AND L26
E BUCHHOLZ H/AU
L28 107 S E3-E5,E18,E19
E BUECHHOLZ H/AU
E BEUCHHOLZ H/AU
E MEDUSKI J/AU
L29 30 S E3-E7
L30 129 S L28,L29
L31 2 S L30 AND L27
L32 28332 S MERCK/PA,CS
L33 3 S L32 AND L27
L34 3 S L31,L33
SEL DN AN 2
L35 1 S L34 AND E1-E3

FILE 'REGISTRY' ENTERED AT 07:31:32 ON 19 AUG 2002

L36 6 S 58-05-9 OR 134-35-0 OR 2800-34-2 OR 3432-99-3 OR 10360-12-0 O
E DIHYDROFOLIC ACID/CN
L37 1 S E3
E TETRAHYDROFOLIC ACID/CN
L38 1 S E3
L39 8 S L36-L38
E C20H25N7O6/MF
L40 31 S E3 AND 46.150.18/RID AND NCNC3-NC2NC2/ES
L41 28 S L40 AND GLUTAMIC ACID
L42 21 S L41 AND HEXAHYDRO
L43 13 S L42 AND 5 METHYL
L44 5 S L43 NOT (LABELED OR 11C# OR 13C# OR 14C# OR C11# OR C13# OR C
L45 21 S C20H23N7O6/MF AND 46.150.18/RID AND NCNC2-NCNC3-NC2NC2/ES
L46 20 S L45 AND GLUTAMIC ACID AND HEXAHYDRO AND 3 AMINO
L47 5 S L46 NOT (LABELED OR 11C# OR 13C# OR 14C# OR C11# OR C13# OR C
L48 4 S L47 NOT 15N#
L49 4 S C20H23N7O6/MF AND 46.150.18/RID AND NCNC3-NC2NC2/ES AND HEXAH
L50 3 S L49 NOT 13C#
L51 6 S C20H22N7O6/MF AND 46.150.18/RID AND NCNC2-NCNC3-NC2NC2/ES AND
L52 4 S L51 NOT (T OR D)/ELS
L53 13 S C19H23N7O6/MF AND GLUTAMIC ACID AND HEXAHYDRO
L54 5 S L53 NOT (LABELED OR 11C# OR 13C# OR 14C# OR C11# OR C13# OR C
L55 4 S L54 NOT 15N#
L56 15 S C19H21N7O6/MF AND 46.150.18/RID AND GLUTAMIC ACID AND TETRAHY
L57 8 S L56 NOT (LABELED OR 11C# OR 13C# OR 14C# OR C11# OR C13# OR C
L58 7 S L57 NOT 188497-71-4
L59 4 S L58 NOT (25512-82-7 OR 83961-83-5 OR 74072-24-5)
L60 26 S L39, L44, L48, L50, L52, L55, L59
L61 2 S GLUTAMIC ACID/CN
L62 1 S D-GLUTAMIC ACID/CN
L63 29 S L60-L62
SEL RN
L64 1304 S E1-E29/CRN

FILE 'HCAPLUS' ENTERED AT 08:43:20 ON 19 AUG 2002

L65 53232 S L63
L66 7701 S L64
L67 76589 S (DIHYDROFOLIC OR TETRAHYDROFOLIC OR METHYLTETRAHYDROFOLIC OR
L68 136 S L27 AND L65-L67
L69 91361 S DIHYDROFOLATE OR TETRAHYDROFOLATE OR METHYLTETRAHYDROFOLATE O
L70 20 S L27 AND L69
L71 2 S L68, L70 AND L34
L72 1 S L71 NOT PESTICIDE
L73 97 S L68, L70 AND (PD<=19981030 OR PRD<=19981030 OR AD<=19981030)
L74 80 S L73 AND L12, L13
L75 20 S L74 AND L16, L17
L76 20 S L75 AND L65, L66
SEL DN AN 2 4 6 12 13 15
L77 6 S L76 AND E30-E47
L78 6 S L72, L77
L79 77 S L73 NOT L76
L80 63 S L79 AND (COMPOSITION OR COMBIN? OR MIX? OR SYNERG? OR COADMIN
L81 14 S L79 NOT L80
SEL HIT RN L78

FILE 'REGISTRY' ENTERED AT 09:09:51 ON 19 AUG 2002

L82 18 S E48-E65
L83 5 S L82 AND L8, L9
L84 6 S L82 AND L10, L11
L85 7 S L82 AND L63, L64

FILE 'REGISTRY' ENTERED AT 09:10:25 ON 19 AUG 2002

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 09:10:50 ON 19 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Aug 2002 VOL 137 ISS 8
 FILE LAST UPDATED: 18 Aug 2002 (20020818/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all hitstr tot 178

L78 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS
 AN 2000:314527 HCAPLUS
 DN 132:326078
 TI Compositions for the treatment and prevention of cardiovascular diseases
 IN Buchholz, Herwig; Meduski, Jerzy D.
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 17


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000025764	A2	20000511	WO 1999-EP7689	19991013 <--
	WO 2000025764	A3	20000713		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9964709	A1	20000522	AU 1999-64709	19991013 <--
	BR 9914815	A	20010703	BR 1999-14815	19991013 <--
	EP 1124548	A2	20010822	EP 1999-952559	19991013 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	US 1998-106205P	P	19981030		<--

WO 1999-EP7689 W 19991013


- AB Compns. comprising one or more active ingredients and, optionally, one or more nutritional substances, solid, liq. and/or semiliquid excipients or auxiliaries, wherein the active ingredients consist of a) a consisting of one or more compds. selected from Me and methylene donors, b) a consisting of one or more Me transporters, and c) a consisting of one or more **bioflavonoids** are well-suited for the treatment and prevention of transmethylation disorders, preferably cardiovascular diseases such as atherogenic and thrombogenic diseases. A compn. was prepd. contg. **betaine** 600, Ca L-5-methyltetrahydrofolate 0.5, and **isoquercetin** 500 mg.
- ST cardiovascular disease pharmaceutical; methyl transporter cardiovascular disease pharmaceutical; **bioflavonoid** cardiovascular disease pharmaceutical
- IT **Flavonoids**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioflavonoids; compns. for treatment and prevention of cardiovascular diseases)
- IT Cardiovascular agents
 Nutrients
 (compns. for treatment and prevention of cardiovascular diseases)
- IT Drug delivery systems
 (tablets; compns. for treatment and prevention of cardiovascular diseases)
- IT Methylation
 (transmethylation, biol., disorders; compns. for treatment and prevention of cardiovascular diseases)
- IT 56-45-1, L-Serine, biological studies 58-05-9
 107-43-7, Betaine 107-97-1, Sarcosine
 117-39-5, Quercetin 134-35-0, 5-Methyltetrahydrofolic acid 153-18-4, Rutin 482-35-9, Isoquercetin 482-36-0, Hyperin 491-50-9, Quercimeritrin 1118-68-9, Dimethylglycine 2800-34-2, 10-Formyltetrahydrofolate 3432-99-3 10360-12-0 20229-56-5, Spiraeosid 139418-88-5, L-Glutamic acid, N-[4-[[[(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for treatment and prevention of cardiovascular diseases)
- IT 56-45-1, L-Serine, biological studies 58-05-9
 107-43-7, Betaine 107-97-1, Sarcosine
 117-39-5, Quercetin 134-35-0, 5-Methyltetrahydrofolic acid 153-18-4, Rutin 482-35-9, Isoquercetin 482-36-0***, ***Hyperin 491-50-9, Quercimeritrin 1118-68-9, Dimethylglycine 2800-34-2, 10-Formyltetrahydrofolate 3432-99-3 10360-12-0 20229-56-5, Spiraeosid 139418-88-5, L-Glutamic acid, N-[4-[[[(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for treatment and prevention of cardiovascular diseases)
- RN 56-45-1 HCAPLUS
- CN L-Serine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-05-9 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 107-43-7 HCAPLUS
 CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 107-97-1 HCAPLUS
 CN Glycine, N-methyl- (9CI) (CA INDEX NAME)




RN 117-39-5 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)



RN 134-35-0 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153-18-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 482-35-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 482-36-0 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 491-50-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-3,5-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1118-68-9 HCAPLUS
 CN Glycine, N,N-dimethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)

Me₂N-CH₂-CO₂H


RN 2800-34-2 HCAPLUS
 CN L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny)l)methyl]formylamino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3432-99-3 HCAPLUS
 CN L-Glutamic acid, N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10360-12-0 HCAPLUS
 CN Imidazo[1,5-f]pteridinium, 3-amino-8-[4-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]phenyl]-1,2,5,6,6a,7-hexahydro-1-oxo-, (6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 20229-56-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[4-(.beta.-D-glucopyranosyloxy)-3-hydroxyphenyl]-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139418-88-5 HCAPLUS

CN L-Glutamic acid, N-[4-[[2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x Ca

L78 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:473951 HCAPLUS

DN 129:126908

TI Composition for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid

IN De Paoli Ambrosi, Gianfranco
 PA Italy
 SO Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K007-48
 ICS A61K031-00; A61K038-16; A61K031-70
 CC 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 852946	A2	19980715	EP 1997-830609	19971117 <--
	EP 852946	A3	19980916		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6147054	A	20001114	US 1997-971436	19971117 <--
	CA 2219849	AA	19980529	CA 1997-2219849	19971121 <--
PRAI	IT 1996-BS94	A	19961129	<--	
AB	A compn. is disclosed for cosmetic, pharmaceutical or dietetic use and including as the active ingredient, at least one of the substances which include acetylglucosamine and glucuronic acid in combination with the active ingredients which belong to the chem. class of the carboxylic acids, .alpha.-hydroxy acids, vitamins, amino acids, and . bioflavonoids , and formulated with particular synergists, additives, and excipients for external use or for internal use.				
ST	cosmetic formulation aminosugar polyhydroxy acid drug				
IT	Carbohydrates, biological studies RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (aldoses; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)				
IT	Carbohydrates, biological studies RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (amino sugars; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)				
IT	Bilberry (anthocyanins of; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)				
IT	Flavonoids RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (bioflavonoids; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)				
IT	Drug delivery systems (capsules; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)				
IT	Aloe barbadensis Calendula officinalis Centella asiatica Cosmetics Drugs Echinacea angustifolia Equisetum arvense Grape Hamamelis virginiana Horse chestnut (Aesculus hippocastanum) Lemon (Citrus limon)				

- Licorice (*Glycyrrhiza glabra*)
 Rue (*Ruta graveolens*)
Silybum marianum
Terminalia sericea
Vaccinium myrtillus
 (compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Amino acids, biological studies
 Anthocyanins
 Flavonoids
 Isoflavonoids
 Saponins
 Terpenes, biological studies
 Triterpenes
 Vitamins
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Carboxylic acids, biological studies
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (dicarboxylic; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Cosmetics
 (emulsions, water-in-oil; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Carboxylic acids, biological studies
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (hydroxy, polycarboxylic; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Carboxylic acids, biological studies
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (hydroxy; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Drug delivery systems
 (injections; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Carbohydrates, biological studies
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (ketoses; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Orange
 (sour; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT Drug delivery systems
 (tablets; compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)
- IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 52-90-4, Cysteine, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-84-8, L-Aspartic acid, biological studies 56-85-9, Glutamine, biological studies 56-86-0, Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 58-85-5, Biotin

59-30-3, Folic acid, biological studies 59-43-8, Vitamin b1, biological studies 59-67-6, Nicotinic acid, biological studies 60-18-4, Tyrosine, biological studies 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 61-90-5, Leucine, biological studies 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, L-Arginine, biological studies 77-92-9, biological studies 79-14-1, Glycolic acid, biological studies 79-83-4, Pantothenic acid 83-88-5, Vitamin b2, biological studies 87-69-4, biological studies 90-64-2 98-92-0, Nicotinamide 116-31-4, Retinal **117-39-5**, **Quercetin** 147-85-3, Proline, biological studies 150-13-0 **153-18-4D**, **Rutin**, derivs. 302-79-4, Retinoic acid 463-40-1, Linolenic acid 464-92-6, Asiatic acid 471-53-4, Glycyrrhetic acid 480-17-1, Leucocyanidin **482-35-9**, **Isoquercetin** 495-62-5, Bisabolene 506-32-1, Arachidonic acid 520-27-4, Diosmin 528-58-5, Cyanidin 1398-61-4, Chitin 6556-12-3, D-Glucuronic acid 6805-41-0, Escin 6915-15-7, Malic acid 7235-40-7, .beta.-Carotene 7512-17-6, Acetylglucosamine 8059-24-3, Vitamin b6 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies 16830-15-2, Asiaticoside 18449-41-7, Madecassic acid 24967-94-0, Dermatan sulfate 29656-58-4, Hydroxybenzoic acid 32449-92-6, Glucuronolactone 34540-22-2, Madecassoside 35054-79-6, Hydroxybutyric acid 55306-03-1, Sericic acid 55306-04-2, Sericoside 65666-07-1, Silymarin 82854-37-3, Echinacoside 105815-90-5, Echinacin
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)

IT **56-45-1**, **Serine**, biological studies **56-86-0**, **Glutamic acid**, biological studies **117-39-5**, **Quercetin 153-18-4D**, **Rutin**, derivs. **482-35-9**, **Isoquercetin**


RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(compn. for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid)

RN 56-45-1 HCAPLUS

CN L-Serine (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 56-86-0 HCAPLUS

CN L-Glutamic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 117-39-5 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI)
 (CA INDEX NAME)




RN 153-18-4 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 482-35-9 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1994:708376 HCAPLUS

DN 121:308376

TI Treatment of arthritic conditions

IN Koppel, Richard M.; Verebey, Karl

PA USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K033-32

ICS A61K035-78; A61K033-26; A61K031-70

NCL 424639000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5358720	A	19941025	US 1993-139742	19931022 <--
AB	A regimented therapeutic method for the alleviation of arthritic conditions by orally administering a selective combination of vitamins and minerals in scheduled dosage amounts. The daily scheduled regimen involves the administration of about 25-100 mg of nicotinic acid three times per day, about 200-1000 mg of calcium ascorbate three times a day, and a single dosage form of a copper-free multivitamin with multiminerals to be taken once a day.				
ST	arthritis vitamin mineral				
IT	Minerals				
	Vitamins				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(treatment of arthritis)				
IT	Inflammation inhibitors				
	(antiarthritics, vitamins and minerals in treatment of arthritis)				
IT	50-81-7, Vitamin C, biological studies 56-86-0, Glutamic acid, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 59-67-6, Nicotinic acid, biological studies 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Vitamin B2, biological studies 87-67-2, Choline bitartrate, biological studies 87-89-8, myo-Inositol 98-92-0, Niacinamide 150-13-0, PABA 153-18-4, Rutin				

520-26-3D, Hesperidin, complex **590-46-5, Betaine**
 hydrochloride 1406-16-2, Vitamin D 1406-18-4, Vitamin E 5743-27-1,
 Calcium ascorbate 7439-89-6, Iron, biological studies 7439-95-4,
 Magnesium, biological studies 7439-96-5, Manganese, biological studies
 7440-09-7, Potassium, biological studies 7440-66-6, Zinc, biological
 studies 7440-70-2, Calcium, biological studies 7553-56-2, Iodine,
 biological studies 7782-49-2, Selenium, biological studies 8059-24-3,
 Vitamin B6 11103-57-4, Vitamin A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of arthritis)


IT **56-86-0, Glutamic acid**, biological studies
153-18-4, Rutin **590-46-5, Betaine**
 hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of arthritis)

RN 56-86-0 HCAPLUS

CN L-Glutamic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153-18-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 590-46-5 HCAPLUS

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

Me₃⁺N-CH₂-CO₂H

● Cl⁻

L78 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1989:472962 HCAPLUS

DN 111:72962

TI Pharmaceuticals containing Eleutherococcus extracts for the inhibition of ethanol addiction

IN Mudzhiri, L. A.; Alkhazashvili, G. G.; Kalatozishvili, E. I.; Chekurishvili, G. O.; Brekhman, I. I.; Bulanov, A. E.; Polozhentseva, M. I.

PA Institute of Sea Biology, Vladivostok, USSR; Scientific-Research Institute of Horticulture, Viticulture, and Wine Making

SO Brit. UK Pat. Appl., 77 pp.

CODEN: BAXXDU

DT Patent

LA English

IC ICM A61K031-195

ICS A61K031-05; A61K031-70; A61K031-715; A61K035-78

CC 4-7 (Toxicology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2198041	A1	19880608	GB 1987-6977	19870324 <--
	GB 2198041	B2	19910605		
PRAI	GB 1986-28228		19861126	<--	

AB Pharmaceuticals for the inhibition of the development of pathol. addiction to EtOH comprise a mixt. of flavonoids, leucoanthocyanins, sterols, amino acids, etc. which lowers the toxic effects of EtOH; when added to alc. beverages, the resulting compns. have good organoleptic properties. A compn. (473 kg) contg. leucoanthocyanins 219, catechins 153, flavonols 81, lignin 68, reducing sugars 216, pectin 16, free amino acids 27, org. acids 36, sterols 4.5, methyl sterols 1.35, dimethyl sterols 1.98, lignans 13.5, lignan glycosides 9, phenolic acids 13.5, phenolic aldehydes 4.5, and alkyl ferulates 4.5 mg/g was added to 4950 kg plum alc., 95 kg sugar, 1.8 kg citric acid, and 28 kg color tint and sufficient EtOH-H₂O to give a beverage contg. 40 vol.% alc.; the beverage was heated for 5 h to 80.degree., cooled to 0-1.degree., filtered, and allowed to stand for 10 days at 20-22.degree.. Rats with a high tolerance toward EtOH were administered drinking water contg. 15% EtOH and the compn. described above (1 mL/50 mL). After 13 wk of administration, the rats were deprived of EtOH for 10 days. Beginning from the 8th wk a trend toward reduced EtOH consumption in the treated animals was seen when offered H₂O or EtOH-contg. H₂O; after deprivation, the EtOH consumption increased in the nontreated controls by 12%, whereas in the treated animals it did not; the treated animals also did not show withdrawal symptoms. This compn. was also administered to humans in the form of alc.-contg. beverages and the total redn. of consumption over a 10-mo period was 28.01%.

ST flavonoid leucoanthocyanin sterol alcoholism beverage

IT Amino acids, biological studies

Carbohydrates and Sugars, biological studies

Carboxylic acids, biological studies

Flavanols

Leucoanthocyanins

Lignans

- RL: BIOL (Biological study)
(ethanol addiction inhibition with compn. contg.)
- IT Lignans
RL: BIOL (Biological study)
(glycosides, ethanol addiction inhibition with compn. contg.)
- IT Steroids, biological studies
RL: BIOL (Biological study)
(hydroxy, ethanol addiction inhibition with compn. contg.)
- IT Steroids, biological studies
RL: BIOL (Biological study)
(hydroxy Me, ethanol addiction inhibition with compn. contg.)
- IT **Glycosides**
RL: BIOL (Biological study)
(lignan, ethanol addiction inhibition with compn. contg.)
- IT **Flavonoids**
RL: BIOL (Biological study)
(oxo hydroxy, ethanol addiction inhibition with compn. contg.)
- IT Aldehydes, biological studies
Carboxylic acids, biological studies
RL: BIOL (Biological study)
(phenolic, ethanol addiction inhibition with compn. contg.)
- IT Mental disorder
(psychosis, from alc., inhibition of, with pharmaceuticals contg. flavonoids and leucoanthocyanins and sterols)
- IT Carbohydrates and Sugars, biological studies
RL: BIOL (Biological study)
(reducing, ethanol addiction inhibition with compn. contg.)
- IT 64-17-5, Ethanol, biological studies
RL: BIOL (Biological study)
(addiction to, inhibition of, with pharmaceuticals contg. flavonoids and leucoanthocyanins and sterols)
- IT 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies **56-45-1, Serine**, biological studies 56-84-8, L-Aspartic acid, biological studies **56-86-0, L-Glutamic acid**, biological studies 56-87-1, Lysine, biological studies 56-89-3, Cystine, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, biological studies 58-86-6, Xylose, biological studies 60-18-4, Tyrosine, biological studies 61-90-5, Leucine, biological studies 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, Arginine, biological studies 77-92-9, Citric acid, biological studies 79-14-1, biological studies 83-46-5 83-48-7 87-69-4, biological studies 99-50-3 99-96-7, biological studies 110-15-6, Succinic acid, biological studies 110-17-8, 2-Butenedioic acid (E)-, biological studies 121-33-5 121-34-6, Vanillic acid 127-22-0, Taraxerol 134-96-3, Syringic aldehyde 138-59-0 144-62-7, Oxalic acid, biological studies 147-81-9, Arabinose 147-85-3, Proline, biological studies 149-91-7, biological studies 154-23-4, (+)-Catechin 328-50-7, .alpha.-Ketoglutaric acid 458-36-6, Coniferyl aldehyde 465-02-1, Germanicol 473-81-4 474-40-8, Citrostenadienol 474-62-4 480-10-4, Astragalin 480-17-1 **482-35-9, Quercetin** -3-glucoside 484-39-9 487-36-5, Pinoresinol 490-46-0, (-)-Epicatechin 491-52-1 512-69-6, Raffinose 520-14-9 520-17-2, Leucopelargonidine 530-57-4, Syringic acid 545-47-1 548-29-8, Isolariciresinol 559-70-6, .beta.-Amyrine 580-72-3, Matairesinol 685-73-4, Galacturonic acid 970-73-0, (+)-Galocatechin 970-74-1, (-)-Epigallocatechin 1059-14-9 1257-08-5, (-)-Epicatechingallate 2955-23-9 4206-58-0, Sinapic aldehyde 6556-12-3, D-Glucuronic acid 6915-15-7 9000-69-5, Pectin 9005-53-2, Lignin, biological studies 16910-32-0, Obtusifoliosin 18594-58-6 29018-62-0 62267-81-6

64190-81-4 64190-82-5 80043-59-0, Oxymatairesinol

RL: BIOL (Biological study)

(ethanol addiction inhibition with compn. contg.)

IT 56-45-1, Serine, biological studies 56-86-0,
L-Glutamic acid, biological studies 482-35-9
, Quercetin-3-glucoside


RL: BIOL (Biological study)

(ethanol addiction inhibition with compn. contg.)

RN 56-45-1 HCAPLUS

CN L-Serine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 56-86-0 HCAPLUS

CN L-Glutamic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 482-35-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1989:121412 HCAPLUS

DN 110:121412

TI Pharmaceuticals containing leucoanthocyanins for the treatment of alcoholism

IN Brekhman, I. I.; Bulanov, A. E.; Polozhentseva, M. I.; Mudzhiri, L. A.;

Alkhazashvili, G. G.; Kalatozishvili, E. I.; Dardymov, I. V.; Bezdetko, G. N.; Khasina, E. I.

PA Institute of Biology of the Sea, Vladivostok, USSR; Scientific-Research Institute of Horticulture, Viticulture, and Wine Making

SO Ger. Offen., 21 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-70

ICS A23L002-26; C12G003-00; A61K031-19; A61K031-195; A61K031-11; A61K031-05; A61K031-35; A61K035-78; A61K031-725; A61K031-215; A61K031-575

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 4


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3641495	A1	19880609	DE 1986-3641495	19861204 <--
	DE 3641495	C2	19910704		
	FR 2607391	A1	19880603	FR 1986-16754	19861201 <--
	FR 2607391	B1	19890331		
	US 4808574	A	19890228	US 1986-937606	19861203 <--
	WO 8911284	A1	19891130	WO 1988-SU127	19880526 <--
	W: JP				
	JP 03501126	T2	19910314	JP 1988-500830	19880526 <--
PRAI	DE 1986-3641495		19861204 <--		
	WO 1988-SU127		19880526 <--		
AB	A pharmaceutical for the treatment of pathol. alc. addiction contains leucoanthocyanins 219-270, catechins 153-187, flavonols 81-99, lignin 68-83, reducing saccharides 216-264, pectin 18-22, free amino acids 27-33, org. acids 36-44, sterols 4.5-5.5, methylsterols 1.35-1.65, dimethylsterols 1.98-2.42, lignans 13.5-16.5, lignan glycosides 9-11, phenolcarboxylic acids 13.5-16.5, phenolaldehydes 4.5-5.5, and alkyl ferulates 4.5-5.5 mg/g. Alc. rats received drinking water contg. 15% EtOH and 1 mL/50 mL of the above mixt. for 13 wk and were then kept abstinent for 10 days; in the abstinent animals the deprivation occurred without alc. withdrawal symptoms. Animals receiving the above mixt. and free to choose water or 15% EtOH-contg. water, decreased their EtOH consumption by 100% after the deprivation period, whereas alc. consumption increased in the control.				
ST	ethanol addiction treatment leucoanthocyanins				
IT	Fatty acids, biological studies				
	Glycerides, biological studies				
	RL: BIOL (Biological study)				
	(of liver, alcoholism treatment with pharmaceuticals contg. leucoanthocyanins in relation to)				
IT	Amino acids, biological studies				
	Flavanols				
	Lignans				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. leucoanthocyanins and, for treatment of alcoholism)				
IT	Leucoanthocyanins				
	RL: BIOL (Biological study)				
	(pharmaceuticals, for treatment of alcoholism)				
IT	Lignans				
	RL: BIOL (Biological study)				
	(glycosides, pharmaceuticals contg. leucoanthocyanins and, for treatment of alcoholism)				
IT	Steroids, biological studies				
	RL: BIOL (Biological study)				
	(hydroxy, pharmaceuticals contg. leucoanthocyanins and, for treatment of alcoholism)				
IT	Steroids, biological studies				

- RL: BIOL (Biological study)
(hydroxy Me, pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT **Glycosides**
RL: BIOL (Biological study)
(lignan, pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT Acids, biological studies
RL: BIOL (Biological study)
(org., pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT **Flavonoids**
RL: BIOL (Biological study)
(oxo hydroxy, pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT Aldehydes, biological studies
Carboxylic acids, biological studies
RL: BIOL (Biological study)
(phenolic, pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT 64-17-5, Ethanol, biological studies
RL: BIOL (Biological study)
(addiction, treatment of, pharmaceuticals contg. leucoanthocyans for)
- IT 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies **56-45-1, Serine**, biological studies 56-84-8, L-Aspartic acid, biological studies **56-86-0, Glutamic acid**, biological studies 56-87-1, Lysine, biological studies 56-89-3, Cystine, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Saccharose, biological studies 58-86-6, Xylose, biological studies 60-18-4, Tyrosine, biological studies 61-90-5, Leucine, biological studies 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, Arginine, biological studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 83-46-5, .beta.-Sitosterin 83-48-7, Stigmasterin 87-69-4, Tartaric acid, biological studies 99-96-7, p-Hydroxybenzoic acid, biological studies 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological studies **117-39-5**
117-39-5D, glycosides 121-33-5, Vanillin 121-34-6, Vanillic acid 134-96-3, Syringic aldehyde 138-59-0, Shikimic acid 144-62-7, Oxalic acid, biological studies 147-81-9, Arabinose 147-85-3, Proline, biological studies 149-91-7, Gallic acid, biological studies 154-23-4, Catechin 303-38-8 328-50-7, .alpha.-Ketoglutaric acid 458-36-6 465-02-1 473-81-4, Glyceric acid 474-40-8, Citrosteradienol 474-62-4, Campesterin 480-10-4, Astragalin 487-36-5, Pinoresinol 490-46-0, (-)Epicatechin 512-69-6, Raffinose 520-18-3D, glycosides 529-44-2D, glycosides 530-57-4 530-59-6 545-47-1, Lupeol 548-29-8 559-70-6, .beta.-Amyrin 580-72-3, Matairesinol 638-95-9, .alpha.-Amyrin 685-73-4, Galacturonic acid 970-73-0, Gallocatechin 970-74-1, (-)Epigallo catechin 1059-14-9, Taraxasterol 1257-08-5, (-)Epicatechin gallate 2955-23-9 6556-12-3, Glucuronic acid 6915-15-7, Malic acid 9000-69-5, Pectin 16910-32-0, Obtusifoliol 18594-58-6 20268-71-7, Hydroxymatairesinol 29018-62-0 62267-81-6 64190-81-4, Octadecanol ferulate 64190-82-5
RL: BIOL (Biological study)
(pharmaceuticals contg. leucoanthocyans and, for treatment of alcoholism)
- IT 480-17-1, Leukocyanidine 491-52-1 520-17-2
RL: BIOL (Biological study)
(pharmaceuticals, for treatment of alcoholism)


IT 56-45-1, Serine, biological studies 56-86-0,
 Glutamic acid, biological studies 117-39-5
 117-39-5D, glycosides
 RL: BIOL (Biological study)
 (pharmaceuticals contg. leucoanthocyanins and, for treatment of
 alcoholism)
 RN 56-45-1 HCAPLUS
 CN L-Serine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 56-86-0 HCAPLUS
 CN L-Glutamic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117-39-5 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI)
 (CA INDEX NAME)



RN 117-39-5 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI)
 (CA INDEX NAME)



L78 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2002 ACS
 AN 1985:59554 HCAPLUS
 DN 102:59554
 TI Tobacco filler blends and smoking articles containing them
 IN Teng, Daniel M.
 PA Morris, Philip, Inc., USA
 SO Eur. Pat. Appl., 25 pp.
 CODEN: EPXXDW


DT Patent
 LA English
 IC A24B015-10; A24B013-00; A24B015-12; A24B003-08; A24D001-00
 CC 11-7 (Plant Biochemistry)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 110693	A1	19840613	EP 1983-307221	19831125 <--
	EP 110693	B1	19881005		
	R: CH, DE, GB, LI, NL				
	AU 8321054	A1	19840531	AU 1983-21054	19831108 <--
	AU 573189	B2	19880602		
PRAI	US 1982-444928		19821126	<--	
AB	A novel smoking tobacco is comprised of an air-cured bright tobacco harvested by stalk cutting, priming, or a combination of partial priming followed by stalk cutting, contains total reducing sugars 0-6, chlorogenic acid 0-0.4, rutin 0-0.2, hot water-sols. .apprx.45-55, total ash 12-26%, combined protein and threonine 0-1.0, combined aspartic acid and asparagine 0.5-1.7, and combined glutamic acid and glutamine 0.5-1.6 mg/g (all measurements on a dry wt. basis). Such tobacco, when formulated as a smoking article, provides an aroma and taste of a blended tobacco and may be substituted in whole or in part for burley tobacco in tobacco blends while substantially maintaining the subjective qualities of the burley tobacco and yet, as compared to the burley tobacco-contg. blends, provides a reduced NO content in the smoke.				
ST	tobacco filler smoking compn property				
IT	Alkaloids, biological studies				
	Amino acids, biological studies				
	Carboxylic acids, biological studies				
	Mineral elements				
	RL: BIOL (Biological study)				
	(of air-cured bright tobacco, smoking filler in relation to)				
IT	Aldehydes, biological studies				
	RL: BIOL (Biological study)				
	(of tobacco smoke, from air-cured bright tobacco)				
IT	Tobacco smoke and smoking				
	(tobacco filler blends for)				
IT	Carbohydrates and Sugars, biological studies				
	RL: BIOL (Biological study)				
	(reducing, of air-cured bright tobacco, smoking filler in relation to)				
IT	50-99-7, biological studies 56-40-6, biological studies 56-41-7, biological studies 56-45-1, biological studies 56-84-8, biological studies 56-85-9, biological studies 56-86-0, biological studies 56-87-1, biological studies 57-48-7, biological studies 57-50-1, biological studies 61-90-5, biological studies 63-91-2, biological studies 64-19-7, biological studies 70-47-3, biological studies 72-18-4, biological studies 72-19-5, biological studies 73-32-5, biological studies 77-92-9, biological studies 79-09-4, biological studies 107-92-6, biological studies 110-16-7, biological studies 144-62-7, biological studies 147-85-3, biological studies 153-18-4 327-97-9 7440-70-2, biological studies 7664-41-7, biological studies 7727-37-9, biological studies 14797-55-8, biological studies				
	RL: BIOL (Biological study)				
	(of air-cured bright tobacco, smoking filler in relation to)				
IT	54-11-5 74-90-8, biological studies 630-08-0, biological studies 10102-43-9, biological studies				
	RL: BIOL (Biological study)				
	(of tobacco smoke, from air-cured bright tobacco)				
IT	56-45-1, biological studies 56-86-0, biological studies 153-18-4				
	RL: BIOL (Biological study)				
	(of air-cured bright tobacco, smoking filler in relation to)				


RN 56-45-1 HCAPLUS
 CN L-Serine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 56-86-0 HCAPLUS
 CN L-Glutamic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153-18-4 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> fil wpix
 FILE 'WPIX' ENTERED AT 10:08:21 ON 19 AUG 2002
 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 15 AUG 2002 <20020815/UP>
 MOST RECENT DERWENT UPDATE 200252 <200252/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now available in the /ABEX field. An additional search field /BIX is also provided which comprises both /BI and /ABEX <<<

>>> Implied proximity does currently not work in /BIX Searches in this field may be affected <<<

>>> The BATCH option for structure searches has been enabled in WPINDEX/WPIDS and WPIX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech tot

L40 ANSWER 1 OF 4 WPIX (C) 2002 THOMSON DERWENT
AN 2000-365384 [31] WPIX
DNC C2000-110282
TI Composition for treating neurological and pathopsychological diseases comprises **phosphatidylserine** compound, methyl transporter and methyl and/or methylene donor compound.
DC B02 B05
IN BUCHHOLZ, H; MEDUSKI, J D
PA (MERE) MERCK PATENT GMBH
CYC 88
PI WO 2000025793 A1 20000511 (200031)* EN 19p A61K031-66
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG US UZ VN YU ZA ZW
AU 9962022 A 20000522 (200040) A61K031-66
EP 1124559 A1 20010822 (200149) EN A61K031-66
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
ADT WO 2000025793 A1 WO 1999-EP7688 19991013; AU 9962022 A AU 1999-62022
19991013; EP 1124559 A1 EP 1999-948982 19991013, WO 1999-EP7688 19991013
FDT AU 9962022 A Based on WO 200025793; EP 1124559 A1 Based on WO 200025793
PRAI US 1998-106230P 19981030
IC ICM A61K031-66
ICS A61K031-198; A61K031-505; A61K045-06; A61P025-28
ICI A61K031:505; A61K031:198; A61K031-66
AB WO 200025793 A UPAB: 20000630
NOVELTY - Composition comprises one or more active components comprising:
(1) one or more **phosphatidylserine** compounds;
(2) one or more methyl transporters and
(3) one or more methyl and/or methylene donors, but not **phosphatidylserine** compounds and methyl transporting compounds.
The composition optionally contains one or more nutritional substances, solid, liquid and/or semi-liquid excipients or auxiliaries.
ACTIVITY - Neuroprotective; muscular.
MECHANISM OF ACTION - None given.

USE - Useful for preventing and treating transmethylation disorders, preferably neurological and/or pathopsychological diseases associated with hyperhomocysteinemia, particularly depression, premature old age and senility, dementia, Pick's disease, metabolic myelopathy, peripheral neuropathy, neural tube defects in the unborn e.g. anencephaly, spina bifida and encephalocoele, gait disturbance and muscle weakness.

ADVANTAGE - The composition reduces homocysteine levels and improves the transmethylation process.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B05-B01P; B06-D09; B10-A22; B10-B02D; B10-B02H; B10-B02J; B14-J01; B14-J01A1; B14-J01A4; B14-J05; B14-N16

TECH UPTX: 20000630

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred components: (2) Comprises **dihydrofolic acid, tetrahydrofolic acid, 5-methyl- or 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid or 5,10-methylene or 5,10-methenyltetrahydrofolic acid**, preferably L- **5-methyltetrahydrofolic acid**.

(3) Comprises **betaine, dimethylglycine, sarcosine, methionine, S-adenosylmethionine, choline or serine**.

L40 ANSWER 2 OF 4 WPIX (C) 2002 THOMSON DERWENT

AN 2000-365365 [31] WPIX

DNC C2000-110263

TI Compositions for treating transmethylation disorders, especially cardiovascular diseases e.g. atherogenic and thrombogenic diseases, comprise methyl and methylene donors, methyl transporters and bioflavonoids.

DC B02

IN BUCHHOLZ, H; MEDUSKI, J D

PA (MERE) MERCK PATENT GMBH

CYC 88

PI WO 2000025764 A2 20000511 (200031)* EN 16p A61K031-00

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG US UZ VN YU ZA ZW

AU 9964709 A 20000522 (200040) A61K031-00

BR 9914815 A 20010703 (200141) A61K031-00

EP 1124548 A2 20010822 (200149) EN A61K031-205

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

KR 2001080339 A 20010822 (200213) A61K031-205

ADT WO 2000025764 A2 WO 1999-EP7689 19991013; AU 9964709 A AU 1999-64709
19991013; BR 9914815 A BR 1999-14815 19991013, WO 1999-EP7689 19991013; EP
1124548 A2 EP 1999-952559 19991013, WO 1999-EP7689 19991013; KR 2001080339
A KR 2001-705262 20010427

FDT AU 9964709 A Based on WO 200025764; BR 9914815 A Based on WO 200025764; EP
1124548 A2 Based on WO 200025764

PRAI US 1998-106205P 19981030

IC ICM A61K031-00; A61K031-205

ICS A23L001-30; A23L001-302; A23L001-305; A61K031-195; A61K031-35;
A61K031-505

AB WO 200025764 A UPAB: 20000630

NOVELTY - Compositions for treating transmethylation disorders comprise methyl and methylene donors, methyl transporters and bioflavonoids as active ingredients and optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaries.

DETAILED DESCRIPTION - Compositions comprise one or more active

ingredients and optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaries. The active ingredient comprises:

- (a) a component (A) comprising one or more compounds selected from methyl and methylene donors;
- (b) a component (B) comprising one or more methyl transporters; and
- (c) a component (C) comprising one or more bioflavonoids.

An INDEPENDENT CLAIM is also included for the use of one or more compounds selected from methyl and methylene donors, one or more transporters and one or more bioflavonoids in the preparation of a composition for treating transmethylation disorders.

ACTIVITY - Cardiant; antiarteriosclerotic; thrombolytic; hypotensive; cerebroprotective.

USE - For treating and preventing transmethylation disorders, cardiovascular diseases, atherogenic and/or thrombogenic diseases, diseases associated with hyperhomocysteinemia; premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic disease (all claimed).

ADVANTAGE - The compositions are more effective than prior art preparations.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-A01; B06-D09; B10-A22; B10-B02H; B10-B02J; B12-M11B; B14-F01; B14-F02; B14-F04; B14-N16

TECH UPTX: 20000630

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Component (C) comprises one or more compounds selected from mono-, di-, or triglycoside bioflavonoids containing the aglycone **quercetin**.

L40 ANSWER 3 OF 4 WPIX (C) 2002 THOMSON DERWENT

AN 1999-327123 [27] WPIX

DNC C1999-096787

TI Preventing and treating migraine headaches.

DC B05

IN ALLOCCA, J A

PA (ALLO-N) ALLOCCA TECH INC

CYC 82

PI WO 9923881 A1 19990520 (199927)* EN 21p A01N043-38

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
UZ VN YU ZW

US 5939076 A 19990817 (199939) A61K009-00

AU 9913985 A 19990531 (199941) A01N043-38

GB 2348133 A 20000927 (200051) A61K031-405

ADT WO 9923881 A1 WO 1998-US24041 19981110; US 5939076 A US 1997-968358
19971112; AU 9913985 A AU 1999-13985 19981110; GB 2348133 A WO
1998-US24041 19981110, GB 2000-11925 20000517

FDT AU 9913985 A Based on WO 9923881; GB 2348133 A Based on WO 9923881

PRAI US 1997-968358 19971112

IC ICM A01N043-38; A61K009-00; A61K031-405

ICS A01N033-02; A61K009-48; A61K031-198

ICA A61P025-06

ICI A61K031-405, A61K031:198; A61K031-198, A61K031:405

AB WO 9923881 A UPAB: 19990714

NOVELTY - Preventing or treating a migraine headache comprises daily dietary supplementation with serotonin and norepinephrine precursors so

that levels of serotonin and norepinephrine are increased.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a daily supplement which comprises:

(1) a first formulation comprising a serotonin precursor, a methyl donor source, a choline source, a niacin source, a carbohydrate and vitamin B6 and

(2) a second formulation comprising a norepinephrine precursor, a vitamin C source and a copper source.

Folic acid, a bioflavanoid, proanthocyanidins, a source of calcium and/or a source of magnesium are contained in at least one formulation.

ACTIVITY - Antimigraine.

A male patient (aged 48) suffering migraine headaches twice a week for 40 years began taking the daily dietary supplement of serotonin and norepinephrine precursors along with diet adjustment and suffered no further migraine attacks.

MECHANISM OF ACTION - Serotonin and norepinephrine level elevators.

USE - Useful for preventing or alleviating migraine headaches.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-D01; B10-B02E; B14-C01

TECH UPTX: 19990714

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred method: The method comprises administering L-tryptophan or L-5-hydroxytryptophan as the serotonin precursor and L-tyrosine as the norepinephrine precursor and a bioflavanoid, preferably **quercetin**, **rutin** or **hexperidin**.

Preferred Composition: The first formulation comprises (in mg): 1100 magnesium aspartate, 500 anhydrous dextrose, 180 L-5-hydroxytryptophan, 175 calcium ascorbate, 170 inositol hexanicotinate, 170 pyridoxine hydrochloride, 100 choline citrate and 100 **dimethylglycine**. The second formulation comprises (in mg): 500 quercetin, 800 L-tyrosine, 200 calcium ascorbate, 200 magnesium aspartate, 200 calcium citrate, 100 proanthocyanidins, 20 copper sebacate and 400 **folic acid**.

L40 ANSWER 4 OF 4 WPIX (C) 2002 THOMSON DERWENT

AN 1997-279778 [25] WPIX

DNC C1997-089883

TI Treatment and prevention of sickle cell crisis - comprises administration of vitamin, mineral and micronutrient formulations as sustained release compositions.

DC B05

IN LOCKETT, C G; LOCKETT, C

PA (LOCK-I) LOCKETT C G; (LOCK-I) LOCKETT C

CYC 75

PI US 5626884 A 19970506 (199725)* 5p A61K033-32

WO 9850051 A1 19981112 (199851)# EN A61K033-32

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AU 9729932 A 19981127 (199915)# A61K033-32

ADT US 5626884 A US 1995-516737 19950818; WO 9850051 A1 WO 1997-US7122 19970505; AU 9729932 A AU 1997-29932 19970505, WO 1997-US7122 19970505

FDT AU 9729932 A Based on WO 9850051

PRAI US 1995-516737 19950818; WO 1997-US7122 19970505; AU 1997-29932 19970505

IC ICM A61K033-32

ICS A61K031-07; A61K031-34; A61K031-355; A61K031-44; A61K031-51; A61K031-70; A61K033-04; A61K033-06; A61K033-24; A61K033-36; A61K035-78

AB US 5626884 A UPAB: 19970619

Treating or preventing sickle cell crisis in a person having sickle cell disease comprises administering a cumulative daily dosage of vitamin A (8250-250000 I.U.), vitamin B-1 (25-1000 mg), vitamin B-2 (25-1000 mg), vitamin B-6 (25-1000 mg), vitamin C (25-1000 mg), niacinamide (25-1000 mg), para-aminobenzoic acid (25-1000 mg), pantothenic acid (25-1000 mg), choline bitartrate (25-1000 mg), inositol (25-1000 mu g), vitamin B-12 (25-1000 mu g), biotin (25-1000 mu g), vitamin D (100-4000 I.U.), **folic acid** (100-4000 mu g), vitamin E (25-1000 I.U.), **rutin** (8.25-250 mg), citrus bioflavonoid complex (8.25-250 mg), **betaine hydrochloride** (8.25-250 mg), iron (8.25-250 mg), hesperidin complex (1.25-50 mg), calcium (10-400 mg), magnesium (5-100 mg), zinc (5-100 mg), potassium (3.75-150 mg), manganese (1.5-60 mg), iodine (37.5-1500 mu g), chromium (3.75-150 mu g) and selenium (2.5-100 mu g).

ADVANTAGE - The medication may be administered outside a critical care environment. This allows persons suffering from sickle cell disease to lead more productive, normal lives. The constant threat of crisis onset is dramatically reduced, which contributes to greater mental and emotional confidence.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-L; B05-A01A; B05-A01B; B05-A03; B05-B02C; B05-C07; B06-A01; B06-D09; B06-F03; B10-A07; B10-A22; B10-B02A; B10-C02; B14-F03

=> d his

(FILE 'HOME' ENTERED AT 09:54:42 ON 19 AUG 2002)

SET COST OFF

FILE 'WPIX' ENTERED AT 09:54:56 ON 19 AUG 2002

L1	12065	S	?BETAIN? OR ?DIMETHYLGLYCIN? OR (DIMETHYL OR DI METHYL) ()GLYC
			E BETAINE/DCN
			E E3+ALL
L2	389	S	E2 OR 0829/DRN
L3	2	S	E4
L4	29	S	E6
			E DIMETHYLGLYCINE/DCN
			E E4+ALL
L5	40	S	E2
			E SARCOSINE/DCN
			E E3+ALL
L6	101	S	E2
L7	12	S	E4
L8	1	S	E6
L9	2	S	E8
			E SERINE/DCN
			E E3+ALL
L10	1350	S	E2 OR 1654/DRN
L11	134	S	E4
L12	32	S	E6
L13	228	S	E8
L14	12857	S	L1-L13
L15	1161	S	HYPERIN? OR ISOQUERCETIN? OR QUERCETIN? OR ISOQUERCITRIN? OR
			E HPERIN/DCN
			E HYPERIN/DCN
			E E4+ALL
L16	8	S	E2
			E ISOQUERCETIN/DCN
			E E4+ALL
L17	28	S	E2

L18 25 S ISOQUERCITRIN?
E QUERCIMERITRIN/DCN
E SPIRNAEOSID/DCN
E RUTIN/DCN
E E3+ALL
L19 284 S E2 OR 1179/DRN
L20 7 S (RA1RX6 OR RAOICK OR RA1RX7 OR RA1RX8)/DCN
L21 25 S L14 AND L15-L20
E DIHYDROFOLIC ACID/DCN
E E4+ALL
L22 10 S E2
E TETRAHYDROFOLIC ACID/DCN
E E3+ALL
L23 21 S E2
E GLUTAMIC ACID/DCN
E E3+ALL
L24 2292 S E2 OR 0116/DRN
L25 708 S E6 OR 1142/DRN
L26 137 S E8
L27 10 S E10
L28 35 S E12
L29 344 S E14
E METHYL TETRAHYDROFOL/DCN
E METHYLTETRAHYDROFOL/DCN
L30 9 S L21 AND L22-L29
L31 5 S L21 AND ?FOLIC?
L32 1 S L21 AND ?FOLAT?
L33 13 S L30-L32
E R00971+ALL/DCN
L34 269 S E1 OR 0971/DRN
L35 1 S L21 AND L34
L36 2 S RA0ICK/DCN AND L21
L37 13 S L33,L35,L36
L38 2 S RA0055/DCN AND L21
L39 13 S L37,L38
SEL DN AN 4 5 7 8 L39
L40 4 S L39 AND E1-E8

FILE 'WPIX' ENTERED AT 10:08:21 ON 19 AUG 2002